TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT02083783 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG: TRI102
OTHER: Placebo

Sponsor

Tris Pharma, Inc.